Jubilant Pharmova tax demand of Rs 22.10 crores deleted

1 min read     Updated on 17 Jul 2026, 03:14 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Jubilant Pharmova Limited announced that the Income Tax Department has deleted a tax demand of Rs 22.10 crores for Assessment Year 2020-21 following a rectification order received on July 15, 2026. The order addresses a mistake apparent from record. The company continues to pursue a separate appeal on merit grounds before the Income Tax Appellate Tribunal.

powered bylight_fuzz_icon
45827059

*this image is generated using AI for illustrative purposes only.

Jubilant Pharmova Limited has secured a significant financial relief after the Income Tax Department deleted a tax demand of Rs 22.10 crores for Assessment Year 2020-21. The company received the rectification order at 10:06 pm IST on July 15, 2026, which nullifies the demand in its entirety. This development follows a rectification application the company filed against the demand raised by the Income Tax Department.

The order pertains to a mistake apparent from record in the assessment order. While the rectification order has provided relief from the relevant Assessing Officer, the company stated that an appeal filed before the Income Tax Appellate Tribunal (ITAT) on different grounds is yet to be adjudicated. The disclosure was made to the exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Details of the Order

The rectification application was filed to address the specific tax demand for the financial period in question. The successful deletion of the demand removes a potential financial liability for the company. However, the ongoing proceedings before the ITAT indicate that other aspects of the assessment are still under review.

Sr. No. Brief details of Litigation Name of the opposing party Court/tribunal/ Agency where litigation is filed Expected financial implications Quantum of claims (in Rs. crores)
1 Company has received the Rectification Order dated July 15, 2026, for AY 2020-21 deleting the impugned tax demand of Rs 22.10 crores in its entirety. Income Tax Department Rectification application was filed with the Assessing Officer for rectification of mistake apparent from record in the assessment order. The appeal filed before ITAT on different grounds is yet to be adjudicated. The Company has got the relief from the relevant Assessing Officer Rs 22.10 crores

The company confirmed that the order has been posted on its website. Naresh Kapoor, Company Secretary, signed the disclosure on behalf of Jubilant Pharmova Limited .

Historical Stock Returns for Jubilant Pharmova

1 Day5 Days1 Month6 Months1 Year5 Years
+1.45%-3.02%+2.43%+1.58%-16.76%+45.54%

What is the expected timeline for the adjudication of the pending appeal before the Income Tax Appellate Tribunal?

How will the deletion of the Rs 22.10 crore tax demand impact Jubilant Pharmova's cash flow and capital allocation strategies in the upcoming fiscal year?

Could this rectification order set a precedent for resolving other ongoing tax disputes the company may face?

Jubilant Pharmova subsidiary to appeal Rs 53.37 Cr tax disallowance

1 min read     Updated on 01 Jul 2026, 04:02 AM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Jubilant Pharmova Ltd's subsidiary Jubilant Biosys received a rectification order disallowing brought forward losses of Rs 53.37 crore for AY 2019-20. The company plans to file an appeal before the National Faceless Appeal Centre (NFAC) and does not expect material financial impact.

powered bylight_fuzz_icon
44377996

*this image is generated using AI for illustrative purposes only.

Jubilant Pharmova Ltd's wholly owned subsidiary, Jubilant Biosys Limited, received a rectification order from the jurisdictional Assessing Officer in Noida for Assessment Year 2019-20, disallowing brought forward losses of Rs 53.37 crore. The order, dated June 29, 2026, amends the assessment under Section 143(1) of the Income-tax Act, 1961, for Financial Year 2018-19. The company believes the tax adjustment ignored facts and legal provisions and plans to challenge the decision.

The subsidiary is preparing to file an appeal before the National Faceless Appeal Centre (NFAC), the first-level Appellate Authority. Management expects the impugned adjustment to be deleted post-adjudication and does not anticipate any material adverse financial implications from the order. The event was reported to the exchanges on June 30, 2026.

The tax dispute centers on the disallowance of losses carried forward from previous years. The Assessing Officer in Noida rejected the claim, leading to a potential tax liability for the subsidiary. The company maintains that the order is not sustainable under the provisions of law.

Details of the Rectification Order

Sr. No. Brief details of Litigation Name of the opposing party Court/tribunal/ Agency where litigation is filed Expected financial implications Quantum of claims (in Rs. crores)
1 Rectification order dated June 29, 2026 amending assessment u/s 143(1) of the Income-tax Act, 1961, passed by the jurisdictional Assessing Officer in Noida for Assessment Year 2019-20 (Financial Year 2018-19) disallowing the claim of brought forward losses of Rs. 53.37 crores DCIT, Noida Company is in the process of filing an appeal before National Faceless Appeal Centre (NFAC) Company is in the process of filing an appeal before first level Appellate Authority (National Faceless Appeal Centre - NFAC) against the rectification order and expects to get relief from the Appellate Authority and does not anticipate any material adverse financial implication Disallowance of claim of brought forward losses of Rs. 53.37 crores

The filing was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The document has been posted on the company's website.

Historical Stock Returns for Jubilant Pharmova

1 Day5 Days1 Month6 Months1 Year5 Years
+1.45%-3.02%+2.43%+1.58%-16.76%+45.54%

What is the expected timeline for the National Faceless Appeal Centre (NFAC) to adjudicate the appeal?

Could this tax dispute influence Jubilant Pharmova's dividend policy or capital allocation plans in the near term?

How might the outcome of this case set a precedent for similar brought forward loss claims by other pharmaceutical companies?

More News on Jubilant Pharmova

1 Year Returns:-16.76%